Analytical Data
-
Gene name
TAC1
- Application
-
Alternative Names
TAC1；KIAA1103；Transforming acidic coiled-coil-containing Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20366
-
Expression Region
20-129aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSHMEEIGA NDDLNYWSDW YDSDQIKEEL PEPFEHLLQR IARRPKPQQF FGLMGKRDAD SSIEKQVALL KALYGHGQIS HKRHKTDSFV GLMGKRALNS VAYERSAMQN YERRR
-
Molecular Weight
16 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TAC1, or Tachykinin Precursor 1, is a crucial protein involved in various physiological processes, including neurogenic inflammation, pain perception, and gastrointestinal motility. This research focuses on the recombinant expression of TAC1 to explore its functional roles and potential therapeutic applications. Recent studies have highlighted the involvement of TAC1-derived neuropeptides, such as substance P and neurokinin A, in mediating pain responses and influencing the central nervous system. Consequently, understanding the structure and function of TAC1, as well as developing efficient methods for its recombinant production, could lead to significant advancements in pain management and treatments for related disorders. The successful expression of TAC1 in host systems has enabled the exploration of its biochemical properties, receptor interactions, and downstream signaling pathways. Additionally, engineered TAC1 variants may provide insights into the modulation of neuropeptide activity and offer novel strategies for drug development. Given the increasing interest in neuropeptides as therapeutic targets, TAC1 recombinant protein research holds promise for uncovering new avenues in treating chronic pain and other related conditions, ultimately contributing to the field of neurobiology and pharmacotherapy.
